Home blood transfusions for people with advanced blood cancers in hospice

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The HEME-Hospice program offers palliative red blood cell and platelet transfusions at home for patients with relapsed or refractory hematologic malignancies who are enrolled in hospice. In a cluster randomized design, hematologic oncologists are randomly assigned to provide access to HEME-Hospice or to continue usual care, and patients receive services based on their physician's assignment. Outcomes include hospice enrollment, patient quality of life and mood, end-of-life healthcare utilization, and caregiver quality of life and mood. The trial is run through Dana-Farber and Brigham and Women's Hospital for patients living in the Care Dimensions Hospice catchment who receive primary oncology care at Dana-Farber.

Why it matters

Who can join: the full rules

Inclusion Criteria for Patient Participants:

* Diagnosis of a relapsed/refractory hematologic malignancy
* Age ≥ 18 years
* Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)
* Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction
* Patient resides within catchment served by Care Dimensions Hospice
* Physician-estimated prognosis of six months or less

Inclusion Criteria for Caregivers:

* Identified informal caregiver of enrolled patient with hematologic malignancy
* Age ≥ 18 years

Exclusion Criteria for Patient Participants:

* Age \< 18 years
* Already enrolled in hospice
* Resides in nursing home or assisted living facility
* History of previous serious adverse transfusion reaction

Exclusion Criteria for Caregivers:

-Age \< 18 years

Where it's running

• Brigham and Women's Hospital
  Boston, Massachusetts, United States Recruiting
• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Oreofe Odejide, MD, MPH — Dana-Farber Cancer Institute
• Study coordinator: Oreofe Odejide, MD, MPH
• Email: Oreofe_Odejide@dfci.harvard.edu
• Phone: 617-632-6864

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Improving outcomes for stem cell transplant patients using an intervention website

  This study is testing if a special website can help adults with blood cancer feel better and improve their quality of life after a stem cell transplant compared to a regular educational website.

  Recruiting at 3 sites Northwestern University · Washington D.C., District of Columbia and 2 other locations · NCT06960993

• Impact of Leukemia and Lymphoma Society services on blood cancer patients

  This study is testing how the services provided by the Leukemia and Lymphoma Society can help people with blood cancers feel better and manage their care over six months.

  Recruiting University of Miami · Miami, Florida and 2 other locations · NCT05745285

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Telehealth music therapy for cognitive difficulties in blood cancer survivors

  This program will test whether telehealth music therapy can help adults who survived leukemia, lymphoma, or myeloma and who are having trouble with memory, attention, or thinking.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07052916

• Best germline DNA source to guide drug dosing after allogeneic stem cell transplant

  This project will test whether blood, skin, or other tissue samples give the most reliable genetic information to guide medicine dosing for adults who receive an allogeneic stem cell transplant.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06856226

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.